From MarketBeat:

Praxis Precision Medicines, Inc. saw short interest climb 57.5% in December, total shares of 371,000. Short interest ratio is 5.1 days based on average trading volume of 73,200 shares. (source: marketbeat.com)

Institutional investors and hedge funds increased their stake in Praxis Precision Medicines, including Vanguard, Citigroup, and GSA Capital Partners. Overall analysts predict the stock to post -19.9 earnings per share for the year. (source: marketbeat.com)

Praxis Precision Medicines stock decreased by 0.3%. The company traded down $0.12 on Friday, with a trading volume of 318,781 shares. The stock has a market capitalization of $371.68 million and a one year low of $11.85 and high of $78.75. (source: marketbeat.com)

Praxis Precision Medicines last report revealed a 47 million revenue, beating analysts’ consensus estimates of ($5.25) by $2.55. The company currently has an average rating of “Moderate Buy” and a consensus price target of $94.67. (source: marketbeat.com)

Praxis Precision Medicines, Inc. develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing multiple clinical trials for several treatments. (source: marketbeat.com)



Read more: Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Sees Significant Growth in Short Interest